Valuation: Polaris Group

Market Cap 1.17TCr 37Cr 32Cr 30Cr 28Cr 52Cr 3.46TCr 53Cr 354.95Cr 137.8Cr 1.71TCr 137.59Cr 134.52Cr 5.95TCr P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 1.22TCr 38Cr 33Cr 31Cr 29Cr 54Cr 3.62TCr 55Cr 370.7Cr 143.91Cr 1.78TCr 143.7Cr 140.49Cr 6.22TCr EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
34.02%
Yield 2024 *
-
Yield 2025 -
1 day+2.26%
1 week+3.44%
1 month+0.37%
3 months-29.24%
6 months-56.43%
Current year-56.43%
1 week 12.5
Extreme 12.5
13.6
1 month 12.5
Extreme 12.5
13.75
Current year 12.5
Extreme 12.5
35.95
1 year 12.5
Extreme 12.5
44.55
3 years 12.5
Extreme 12.5
91.1
5 years 12.5
Extreme 12.5
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%+3.44%-64.90%-83.39% 36Cr
+1.15%+5.94%-3.40%+2.32% 4.66TCr
-2.77%+10.48%+409.05%+600.11% 4.1TCr
-0.03%+12.81%+22.61%-14.04% 3.23TCr
-1.73%+3.20%+17.72%+59.83% 3.22TCr
-3.29%+7.98%+14.01%+29.96% 2.55TCr
+1.15%+11.79% - - 1.64TCr
-0.96%+11.85%+68.73%+120.51% 1.53TCr
+0.56%+5.09%+13.43%+17.88% 1.36TCr
-1.74%+4.34%+100.68%+93.25% 1.33TCr
Average -0.54%+6.77%+64.22%+91.83% 2.37TCr
Weighted average by Cap. -0.89%+7.70%+94.48%+137.26%

Financials

2024 2025
Net sales 11Cr 33.63L 29.44L 27.17L 25.35L 47.76L 32Cr 48.61L 3.26Cr 1.27Cr 16Cr 1.26Cr 1.24Cr 55Cr 4.06Cr 12.76L 11.17L 10.31L 10L 18.12L 12Cr 18.45L 1.24Cr 48.02L 5.95Cr 47.95L 46.88L 21Cr
Net income -250.26Cr -7.87Cr -6.89Cr -6.36Cr -5.93Cr -11Cr -743.76Cr -11Cr -76Cr -30Cr -367.02Cr -30Cr -29Cr -1.28TCr -392.71Cr -12Cr -11Cr -9.97Cr -9.3Cr -18Cr -1.17TCr -18Cr -119.63Cr -46Cr -575.93Cr -46Cr -45Cr -2.01TCr
Net Debt 91.92L 3L 3L 2L 2L 4L 2.73Cr 4L 28L 10.87L 1.35Cr 10.85L 10.61L 4.7Cr 52Cr 1.62Cr 1.42Cr 1.31Cr 1.22Cr 2.31Cr 153.62Cr 2.35Cr 16Cr 6.11Cr 76Cr 6.1Cr 5.97Cr 264.08Cr
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
30/26/30 NT$13.55 +2.26% 12,74,774
29/26/29 NT$13.25 +6.00% 15,13,600
26/26/26 NT$12.50 -4.21% 21,71,938
25/26/25 NT$13.05 -3.69% 12,46,733
24/26/24 NT$13.55 +3.44% 12,60,121
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock